Clonidine XR Shortage: What Providers and Prescribers Need to Know in 2026

Provider Briefing: Clonidine XR Supply Disruptions in 2026

If your patients are reporting difficulty filling Clonidine XR prescriptions, they're not exaggerating. The extended-release formulation of Clonidine Hydrochloride — marketed as Kapvay and available generically — has experienced significant supply disruptions that continue into 2026.

This briefing provides prescribers with an up-to-date picture of the shortage, its clinical implications, and actionable strategies for maintaining continuity of care for your ADHD patients.

Shortage Timeline and Current Status

The supply challenges with Clonidine ER tablets have been building since 2022:

• 2022-2023: Initial reports of intermittent shortages as some generic manufacturers reduced production or exited the market.
• 2024: The FDA listed Clonidine Hydrochloride Extended-Release Tablets under supply disruption monitoring. Multiple NDCs were flagged for limited availability.
• 2025: Additional manufacturer discontinuations reduced the number of active generic producers. The FDA categorized certain formulations under a discontinuation status.
• 2026 (current): Generic Clonidine ER remains available from a reduced number of manufacturers, but supply is inconsistent. Some pharmacies report regular stock while others cannot source the product at all. The brand product (Kapvay) is rarely stocked.

The FDA's drug shortage database classifies Clonidine Hydrochloride Extended-Release Tablets under the Psychiatry therapeutic category with a discontinuation notation for certain manufacturers.

Prescribing Implications

The supply constraints create several clinical considerations for prescribers:

Formulation Non-Interchangeability

Clonidine ER and Clonidine IR are not bioequivalent on a milligram-per-milligram basis. The extended-release formulation has different pharmacokinetic properties — slower absorption, longer Tmax, and more sustained plasma levels. Patients should not substitute IR for ER without dose recalculation and clinical oversight.

Rebound Hypertension Risk

Abrupt discontinuation of Clonidine — whether due to supply interruption or patient non-adherence — poses a risk of rebound hypertension. This is particularly concerning in pediatric patients who may already have limited health literacy about their medications. If a patient cannot fill their Clonidine XR prescription, a tapering plan or bridge therapy should be arranged promptly.

Comorbidity Considerations

Many patients on Clonidine XR were placed on this agent specifically because of comorbid conditions — anxiety, tic disorders, sleep disturbance, or stimulant side effect mitigation. When considering alternatives, the comorbidity profile should drive therapeutic selection, not just ADHD symptom control.

Prior Authorization Delays

Switching to an alternative agent may trigger prior authorization requirements, especially for brand-name products like Qelbree (Viloxazine ER). Factor in potential delays of 3 to 7 business days when planning transitions.

Current Availability Picture

Based on available data from pharmacy distribution networks and the FDA:

• Generic Clonidine ER 0.1 mg tablets: Intermittently available. Some wholesalers report stock; others do not. Independent pharmacies with multiple wholesaler relationships may have better access.
• Generic Clonidine ER 0.2 mg tablets: Similar availability constraints as the 0.1 mg strength.
• Kapvay (brand): Rarely stocked at retail pharmacies. Specialty pharmacy sourcing may be required.
• Onyda XR (extended-release suspension): Available from Tris Pharma. This liquid formulation may be an option for patients who cannot find tablets.
• Clonidine IR (Catapres/generic): Widely available with no shortage. Cash price under $10 per month with discount cards.

For real-time pharmacy inventory data, refer your patients to Medfinder for Providers.

Cost and Access Considerations

Cost barriers compound the supply issue:

• Generic Clonidine ER retail price: $90 to $170 per 30 tablets at cash price
• With discount coupons: $18 to $25 per 30 tablets (SingleCare, GoodRx)
• Generic Clonidine IR: Under $10 per month with coupons
• Guanfacine ER (generic): $20 to $50 per month with coupons
• Atomoxetine (generic): $15 to $40 per month with coupons
• Viloxazine ER (Qelbree, brand only): $300+ per month without insurance

For patients without insurance or with high-deductible plans, directing them to discount card programs can reduce their out-of-pocket burden significantly. Patient assistance programs through NeedyMeds and RxAssist may help qualifying patients. See our patient-facing guide on saving money on Clonidine XR.

Tools and Resources for Your Practice

Medfinder for Providers

Medfinder offers real-time pharmacy inventory search, allowing your office to quickly identify pharmacies that currently stock Clonidine XR in your patient's area. This can be integrated into your clinical workflow to reduce the administrative burden on your staff and prevent missed doses for your patients.

FDA Drug Shortage Database

The FDA Drug Shortages page provides official status updates, estimated resupply dates, and manufacturer information. Check this periodically for updates on Clonidine ER availability.

Clinical Decision Support

When switching agents, consider the following decision framework:

1. If the patient needs to stay on an alpha-2 agonist: Guanfacine ER (Intuniv/generic) is the preferred switch. It's more selective for alpha-2A receptors, taken once daily, and generally well-tolerated.
2. If an alpha-2 agonist is not required: Atomoxetine offers broad-age approval and 24-hour coverage. Viloxazine ER (Qelbree) is a newer alternative but carries higher cost.
3. If this is a temporary gap: Clonidine IR with appropriate dose adjustment can bridge the patient until ER supply is restored. Calculate the daily dose carefully — IR and ER are not mg-for-mg equivalent.

For a patient-facing comparison of alternatives, direct patients to our article on alternatives to Clonidine XR.

Looking Ahead

Several factors suggest the Clonidine ER supply situation may gradually improve:

• New ANDA approvals: The FDA continues to prioritize generic drug applications for medications on the shortage list, which could bring new manufacturers to market.
• Onyda XR availability: The extended-release suspension offers an alternative delivery system that increases the overall supply of extended-release Clonidine.
• Market incentives: Ongoing demand creates financial incentive for generic manufacturers to enter or re-enter the Clonidine ER market.

However, in the near term, supply disruptions are likely to continue. Prescribers should plan for potential interruptions and discuss contingency plans with patients proactively.

Final Thoughts

The Clonidine XR shortage requires proactive management at the prescriber level. Key actions include:

• Educating patients about the shortage and the importance of starting refills early
• Documenting contingency plans in the chart (alternative agents, taper protocols)
• Using tools like Medfinder for Providers to direct patients to pharmacies with available stock
• Monitoring the FDA shortage database for updates

For related provider resources, see our article on how to help your patients find Clonidine XR in stock and our guide on helping patients save money on Clonidine XR.